Viral vectors: From virology to transgene expression

British Journal of Pharmacology

Volumn 157, Issue 2, 2009, Pages 153-165

  Bouard, D ^a,b,c,d   Alazard Dany, N ^a,b,c,d   Cosset, F L ^a,b,c,d  

^a UNIVERSITÉ DE LYON   (France)

^b INSERM   (France)

^c UNIVERSITÉ DE LYON   (France)

^d UNIVERSITÉ LYON 1   (France)

Author keywords

AAV; Ad; Cell targeting; Gene therapy; HSV; Lentivectors; Pseudotyping; Transcriptional targeting; Vectors production; Viral vectors

Indexed keywords

VIRUS DNA; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ADENOVIRUS; BIOSAFETY; DNA PACKAGING; DNA REPLICATION; DRUG STABILITY; EX VIVO STUDY; GENE EXPRESSION; GENE INSERTION; GENETIC ENGINEERING; HERPES SIMPLEX VIRUS; HUMAN; IMMUNE RESPONSE; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; REVIEW; TRANSGENE; VIRAL GENE THERAPY; VIROLOGY; ANIMAL; GENE THERAPY; GENE VECTOR; GENETICS; VIRUS;

ANIMALS; GENE THERAPY; GENETIC VECTORS; HUMANS; TRANSGENES; VIRUSES;

EID: 68549087056     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.349     Document Type: Review

References (133)

1. Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A et al. (2002). Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296: 2410-2413. (Pubitemid 34734219)
2. Andreadis S, Roth C, Doux JL, Morgan J, Yarmush M (1999). Largescale processing of recombinant retroviruses for gene therapy. Biotechnol Prog 15: 1-11. (Pubitemid 29087582)
3. Ashworth J, Havranek JJ, Duarte CM, Sussman D, Monnat Jr RJ, Stoddard BL et al. (2006). Computational redesign of endonuclease DNA binding and cleavage specificity. Nature 441: 656-659. (Pubitemid 43927299)
4. Baum C, Kustikova O, Modlich U, Li Z, Fehse B (2006). Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors. Hum Gene Ther 17: 253-263.
5. Beck C, Uramoto H, Boren J, Akyurek LM (2004). Tissue-specific targeting for cardiovascular gene transfer. Potential vectors and future challenges. Curr Gene Ther 4: 457-467. (Pubitemid 39534759)
6. Blouin V, Brument N, Toublanc E, Raimbaud I, Mouiller P, Salvetti A (2004). Improving rAAV production and purification: towards the definition of a scaleable process. J. Gene Med 6 (Suppl 1): S223-S228. (Pubitemid 40228031)
7. Bouard D, Sandrin V, Boson B, Negre D, Thomas G, Granier C et al. (2007). An acidic cluster of the cytoplasmic tail of the RD114 virus glycoprotein controls assembly of retroviral envelopes. Traffic 8: 835-847. (Pubitemid 46971631)
8. Burns JC, Friedmann T, Driever W, Burrascano M, Yee JK (1993). Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci USA 90: 8033-8037. (Pubitemid 23260849)
9. Bushman F (2002a). Constructing the vertebrate genome: evidence from eels that LINEs mobilize SINEs. Mol. Cell 10: 961-962.
10. Bushman FD (2002b). Integration site selection by lentiviruses: biology and possible control. Curr Top Microbiol Immunol 261: 165-177.
11. Campos SK, Barry MA (2007). Current advances and future challenges in adenoviral vector biology and targeting. Curr Gene Ther 7: 189-204. (Pubitemid 46902201)
12. Cattoglio C, Facchini G, Sartori D, Antonelli A, Miccio A, Cassani B et al. (2007). Hot spots of retroviral integration in human CD34 + hematopoietic cells. Blood 110: 1770-1778. (Pubitemid 47443887)
13. Chalberg TW, Portlock JL, Olivares EC, Thyagarajan B, Kirby PJ, Hillman RT et al. (2006). Integration specificity of phage phiC31 integrase in the human genome. J MoI Biol 357: 28-48. (Pubitemid 43339312)
14. Chung JH, Bell AC, Felsenfeld G (1997). Characterization of the chicken beta-globin insulator. Proc Natl Acad Sci USA 94: 575-580.
15. Chung JH, Whiteley M, Felsenfeld G (1993). A 50 element of the chicken beta-globin domain serves as an insulator in human erythroid cells and protects against position effect in Drosophila. Cell 74: 505-514. (Pubitemid 23244616)
16. Cortes ML, Oehmig A, Saydam O, Sanford JD, Perry KF, Fraefel C et al. (2008). Targeted integration of functional human ATM cDNA into genome mediated by HSV/AAV hybrid amplicon vector. Mol Ther 16: 81-88.
17. Cosset FL, Takeuchi Y, Battini JL, Weiss RA, Collins MK (1995). Hightiter packaging cells producing recombinant retroviruses resistant to human serum. J. Virol 69: 7430-7436.
18. Croyle MA, Callahan SM, Auricchio A, Schumer G, Linse KD, Wilson JM etal. (2004). PEGylation of a vesicular stomatitis virus G pseudotyped lentivirus vector prevents inactivation in serum. J. Virol 78: 912-921.
19. Croyle MA, Le HT, Linse KD, Cerullo V, Toietta G, Beaudet A et al. (2005). FEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile. Gene Ther 12: 579-587. (Pubitemid 40468105)
20. Cuchet D, Potel C, Thomas J, Epstein AL (2007). HSV-1 amplicon vectors: a promising and versatile tool for gene delivery. Expert Opin Biol Ther 7: 975-995. (Pubitemid 47208132)
21. Delenda C (2004). Lentiviral vectors: optimization of packaging, transduction and gene expression. J. Gene Med 6 (Suppl 1): S125-S138. (Pubitemid 40228022)
22. Denby L, Work LM, Seggern DJ, Wu E, McVey JH, Nicklin SA et al. (2007). Development of renal-targeted vectors through combined in vivo phage display and capsid engineering of adenoviral fibers from serotype 19p. Mol Ther 15: 1647-1654. (Pubitemid 47289008)
23. DePoIo NJ, Harkleroad CE, Bodner M, Watt AT, Anderson CG, Greengard JS et al. (1999). The resistance of retroviral vectors produced from human cells to serum inactivation in vivo and in vitro is primate species dependent. J. Virol 73: 6708-6714. (Pubitemid 29327853)
24. DePoIo NJ, Reed JD, Sheridan PL, Townsend K, Sauter SL, Jolly DJ et al. (2000). VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum. Mol Ther 2: 218-222.
25. Desmaris N, Bosch A, Salaun C, Petit C, Prevost MC, Tordo N et al. (2001). Production and neurotropism of lentivirus vectors pseudotyped with lyssavirus envelope glycoproteins. Mol Ther 4: 149-156. (Pubitemid 32776507)
26. Dong J, Roth MG, Hunter E (1992). A chimeric avian retrovirus containing the influenza virus hemagglutinin gene has an expanded host range. J. Virol 66: 7374-7382.
27. Duan D, Sharma P, Yang J, Yue Y, Dudus L, Zhang Y et al. (1998). Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J Virol 72: 8568-8577. (Pubitemid 28471794)
28. Ellis J (2005). Silencing and variegation of gammaretrovirus and lentivirus vectors. Hum Gene Ther 16: 1241-1246.
29. Ellis J, Yao S (2005). Retrovirus silencing and vector design: relevance to normal and cancer stem cells? Curr Gene Ther 5: 367-373. (Pubitemid 41052428)
30. ESGT, Board of Directors of (BoDo) (2003). French gene therapy group reports on the adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID). Position statement from the European Society of Gene Therapy. J. Gene Med 5: 82-84.
31. Eto Y, Gao JQ, Sekiguchi F, Kurachi S, Katayama K, Maeda M et al. (2005). PEGylated adenovirus vectors containing RGD peptides on the tip of PEG show high transduction efficiency and antibody evasion ability. J Gene Med 7: 604-612. (Pubitemid 40744526)
32. Fielding AK, Maurice M, Morling FJ, Cosset FL, Russell SJ (1998). Inverse targeting of retroviral vectors: selective gene transfer in a mixed population of hematopoietic and nonhematopoietic cells. Blood 91: 1802-1809. (Pubitemid 28110348)
33. Gansbacher B (2003). Report of a second serious adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID). Position of the European Society of Gene Therapy (ESGT). J. Gene Med 5: 261-262.
34. Ghosh A, Duan D (2007). Expanding adeno-associated viral vector capacity: a tale of two vectors. Biotechnol Genet Eng Rev 24:165-177. (Pubitemid 350032948)
35. Ghosh A, Yue Y, Lai Y, Duan D (2008). A hybrid vector system expands adeno-associated viral vector packaging capacity in a transgeneindependent manner. Mol Ther 16: 124-130.
36. Ghosh A, Yue Y, Long C, Bostick B, Duan D (2007). Efficient wholebody transduction with trans-splicing adeno-associated viral vectors. Mol Ther 15: 750-755. (Pubitemid 46431995)
37. Ginsburg DS, Calos MP (2005). Site-specific integration with phiC31 integrase for prolonged expression of therapeutic genes. Adv Genet 54: 179-187.
38. Girod A, Ried M, Wobus C, Lahm H, Leike K, Kleinschmidt J et al. (1999). Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat Med 5: 1438. (Pubitemid 29439578)
39. Glauser DL, Ackermann M, Saydam O, Fraefel C (2006). Chimeric herpes simplex virus/adeno-associated virus amplicon vectors. Curr Gene Ther 6: 315-324. (Pubitemid 43905448)
40. Goverdhana S, Pun tel M, Xiong W, Zirger JM, Barcia C, Curtin JF et al. (2005). Regulatable gene expression systems for gene therapy applications: progress and future challenges. Mol Ther 12: 189-211.
41. Grimm D, Kleinschmidt JA (1999). Progress in adeno-associated virus type 2 vector production: promises and prospects for clinical use. Hum Gene Ther 10: 2445-2450. (Pubitemid 29489719)
42. Guibinga GH, Friedmann T (2005). Baculovirus GP64-pseudotyped HIV-based lentivirus vectors are stabilized against complement inactivation by codisplay of decay accelerating factor (DAF) or of a GP64-DAF fusion protein. Mol Ther 11: 645-651.
43. Guibinga GH, Hall FL, Gordon EM, Ruoslahti E, Friedmann T (2004). Ligand-modified vesicular stomatitis virus glycoprotein displays a temperature-sensitive intracellular trafficking and virus assembly phenotype. Mol Ther 9: 76-84. (Pubitemid 38208330)
44. Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, De Villartay JP et al. (2002). Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 346: 1185-1193. (Pubitemid 34984579)
45. Hatziioannou T, Delahaye E, Martin F, Russell SJ, Cosset F-L (1999). Retroviral display of functional binding domains fused to the amino-terminus of influenza hemagglutinin. Hum Gene Ther 10: 1533-1544. (Pubitemid 29318990)
46. Hatziioannou T, Valsesia-Wittmann S, Russell S, Cosset F-L (1998). Incorporation of fowl plague virus hemagglutinin into murine leukemia virus particles and analysis of the infectivity of the pseudotyped retroviruses. J Virol 72: 5313-5317. (Pubitemid 28215721)
47. Held PK, Olivares EC, Aguilar CP, Finegold M, Calos MP, Grompe M (2005). In vivo correction of murine hereditary tyrosinemia type I by phiC31 integrase-mediated gene delivery. Mol Ther 11: 399-408. (Pubitemid 40277316)
48. Huang KS, Lo WH, Chung YC, Lai YK, Chen CY, Chou ST et al. (2007). Combination of baculovirus-mediated gene delivery and packedbed reactor for scalable production of adeno-associated virus. Hum Gene Ther 18: 1161-1170.
49. Ishikawa Y, Tanaka N, Murakami K, Uchiyama T, Kumaki S, Tsuchiya S et al. (2006). Phage phiC31 integrase-mediated genomic integration of the common cytokine receptor gamma chain in human T-cell lines. J. Gene Med 8: 646-653. (Pubitemid 43827257)
50. Jager L, Ehrhardt A (2007). Emerging adenoviral vectors for stable correction of genetic disorders. Curr Gene Ther 7: 272-283. (Pubitemid 47240700)
51. Kaptein LC, Greijer AE, Valerio D, van Beusechem VW (1997). Optimized conditions for the production of recombinant amphotropic retroviral vector preparations. Gene Ther 4: 172-176. (Pubitemid 27096142)
52. Kay MA (2007). AAV vectors and tumorigenicity. Nat Biotechnol 25: 1111-1113.
53. Kelly PF, Vandergriff J, Nathwani A, Nienhuis AW, Vanin EF (2000). Highly efficient gene transfer into cord blood nonobese diabetic/ severe combined immunodeficiency repopulating cells by oncoretroviral vector particles pseudotyped with the feline endogenous retrovirus (RD114) envelope protein. Blood 96: 1206-1214. (Pubitemid 30658445)
54. Kobinger GP, Weiner DJ, Yu QC, Wilson JM (2001). Filoviruspseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo. Nat Biotechnol 19: 225-230.
55. Kotani H, Newton III PB, Zhang S, Chiang YL, Otto E, Weaver L et al. (1994). Improved methods of retroviral vector transduction and production for gene therapy. Hum Gene Ther 5: 19-28. (Pubitemid 24310531)
56. Lee SG, Kim S, Robbins PD, Kim BG (1996). Optimization of environmental factors for the production and handling of recombinant retrovirus. Appl Microbiol Biotechnol 45: 477-483. (Pubitemid 126423284)
57. Loewen N, Barraza R, Whitwam T, Saenz DT, Kemler I, Poeschla EM (2003a). FIV vectors. Methods Mol Biol 229: 251-271.
58. Loewen N, Leske DA, Chen Y, Teo WL, Saenz DT, Peretz M et al. (2003b). Comparison of wild-type and class I integrase mutant-FIV vectors in retina demonstrates sustained expression of integrated transgenes in retinal pigment epithelium. J Gene Med 5:1009-1017. (Pubitemid 40310425)
59. Lyons M, Onion D, Green NK, Asian K, Rajaratnam R, Bazan-Peregrino M et al. (2006). Adenovirus type 5 interactions with human blood cells may compromise systemic delivery. Mol Ther 14: 118-128. (Pubitemid 44191831)
60. Maurice M, Mazur S, Bullough FJ, Salvetti A, Collins MKL, Russell SJ et al. (1999). Efficient gene delivery to quiescent IL2-dependent cells by murine leukemia virus-derived vectors harboring IL2 chimeric envelopes glycoproteins. Blood 94: 401-410. (Pubitemid 29323853)
61. Maurice M, Verhoeyen E, Salmon P, Trono D, Russell SJ, Cosset F-L (2002). Efficient gene transfer into human primary blood lymphocytes by surface-engineered lentiviral vectors that display a T cellactivating polypeptide. Blood 99: 2342-2350. (Pubitemid 34525419)
62. McTaggart S, Al-Rubeai M (2002). Retroviral vectors for human gene delivery. Biotechnol Adv 20: 1-31. (Pubitemid 34458446)
63. Medina-Kauwe LK (2003). Endocytosis of adenovirus and adenovirus capsid proteins. Adv Drug Deliv Rev 55: 1485-1496.
64. Merten OW (2004). State-of-the-art of the production of retroviral vectors. J. Gene Med 6 (Suppl 1): S105-S124.
65. Miletic H, Bruns M, Tsiakas K, Vogt B, Rezai R, Baum C et al. (1999). Retroviral vectors pseudotyped with lymphocytic choriomeningitis virus. J. Virol 73: 6114-6116. (Pubitemid 29274903)
66. Miller DG, Wang PR, Petek LM, Hirata RK, Sands MS, Russell DW (2006). Gene targeting in vivo by adeno-associated virus vectors. Nat Biotechnol 24: 1022-1026. (Pubitemid 44215397)
67. Mingozzi F, High KA (2007). Immune responses to AAV in clinical trials. Curr Gene Ther 7: 316-324. (Pubitemid 47595774)
68. Mochizuki H, Schwartz JP, Tanaka K, Brady RO, Reiser J (1998). Hightiter human immunodeficiency virus type 1-based vector systems for gene delivery into nondividing cells. J. Virol 72: 8873-8883. (Pubitemid 28471831)
69. Modlich U, Bohne J, Schmidt M, von Kalle C, Knoss S, Schambach A et al. (2006). Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 108: 2545-2553. (Pubitemid 44776987)
70. Mok H, Palmer DJ, Ng P, Barry MA (2005). Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol Ther 11: 66-79. (Pubitemid 40012000)
71. Montini E, Cesana D, Schmidt M, Sanvito F, Ponzoni M, Bartholomae C et al. (2006). Hematopoietic stem cell gene transfer in a tumorprone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 24: 687-696. (Pubitemid 43882120)
72. Morizono K, Bristol G, Xie Y-M, Kung SK-P, Chen ISC (2001). Antibody-directed targeting of retroviral vectors via cell surface antigens. J Virol 75: 8016-8020.
73. Nakai H, Yant SR, Storm TA, Fuess S, Meuse L, Kay MA (2001). Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J. Virol 75: 6969-6976. (Pubitemid 32641584)
74. Naldini L, Blömer U, Gallay P, Ory D, Mulligan R, Gage FH et al. (1996). In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272: 263-267. (Pubitemid 26119138)
75. Nicklin SA, Wu E, Nemerow GR, Baker AH (2005). The influence of adenovirus fiber structure and function on vector development for gene therapy. Mol Ther 12: 384-393. (Pubitemid 41150124)
76. Nunes FA, Furth EE, Wilson JM, Raper SE (1999). Gene transfer into the liver of nonhuman primates with El-deleted recombinant adenoviral vectors: safety of readministration. Hum Gene Ther 10: 2515-2526.
77. Paques F, Duchateau P (2007). Meganucleases and DNA double-strand break-induced recombination: perspectives for gene therapy. Curr Gene Ther 7: 49-66. (Pubitemid 46322288)
78. Parks RJ, Chen L, Anton M, Sankar U, Rudnicki MA, Graham FL (1996). A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci USA 93: 13565-13570. (Pubitemid 26424159)
79. Peng KW, Morling FJ, Cosset FL, Murphy G, Russell SJ (1997). A gene delivery system activatable by disease-associated matrix metalloproteinases. Hum Gene Ther 8: 729-738. (Pubitemid 27202059)
80. Peng KW, Morling FJ, Cosset F-L, Russell SJ (1998). A retroviral gene delivery system activatable by plasmin. Tumor Target 3: 112-120. (Pubitemid 28500190)
81. Peng KW, Pham L, Ye H, Zufferey R, Trono D, Cosset FL et al. (2001). Organ distribution of gene expression after intravenous infusion of targeted and untargeted lentiviral vectors. Gene Ther 8: 1456-1463. (Pubitemid 32994656)
82. Peng KW, Vile R, Cosset FL, Russell S (1999). Selective transduction of protease-rich tumors by matrix-metalloproteinase-targeted retroviral vectors. Gene Ther 6: 1552-1557. (Pubitemid 29465513)
83. Pensiero MN, Wysocki CA, Nader K, Kikuchi GE (1996). Development of amphotropic murine retrovirus vectors resistant to inactivation by human serum. Hum Gene Ther 7: 1095-1101. (Pubitemid 26202727)
84. Perabo L, Goldnau D, White K, Endell J, Boucas J, Humme S et al. (2006). Heparan sulfate proteoglycan binding properties of adenoassociated virus retargeting mutants and consequences for their in vivo tropism. J. Virol 80: 7265-7269. (Pubitemid 44025223)
85. Ponnazhagan S, Erikson D, Kearns WG, Zhou SZ, Nahreini P, Wang XS et al. (1997). Lack of site-specific integration of the recombinant adeno-associated virus 2 genomes in human cells. Hum Gene Ther 8: 275-284. (Pubitemid 27412263)
86. Porteus MH, Connelly JP, Pruett SM (2006). A look to future directions in gene therapy research for monogenic diseases. PLoS Genet 2: e133.
87. Rabinowitz JE, Rolling F, Li C, Conrath H, Xiao W, Xiao X et al. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol 76: 791-801. (Pubitemid 34033377)
88. Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP et al. (2003). Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 80: 148-158. (Pubitemid 37272241)
89. Rentsendorj A, Xie J, MacVeigh M, Agadjanian H, Bass S, Kim DH et al. (2006). Typical and atypical trafficking pathways of Ad5 penton base recombinant protein: implications for gene transfer. Gene Ther 13: 821-836.
90. Rethwilm A (2007). Foamy virus vectors: an awaited alternative to gammaretro-and lentiviral vectors. Curr Gene Ther 7: 261-271.
91. Rivella S, Callegari JA, May C, Tan CW, Sadelain M (2000). The cHS4 insulator increases the probability of retroviral expression at random chromosomal integration sites. J. Virol 74: 4679-4687. (Pubitemid 30237894)
92. Rogers S, Lowenthal A, Terheggen HG, Columbo JP (1973). Induction of arginase activity with the Shope papilloma virus in tissue culture cells from an argininemic patient. JExp Med 137: 1091-1096.
93. Rosenberg SA, Aebersold P, Cornetta K, Kasid A, Morgan RA, Moen R et al. (1990). Gene transfer into humans - immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 323: 570-578. (Pubitemid 20260084)
94. Saeki Y, Fraefel C, Ichikawa T, Breakefield XO, Chlocca EA (2001). Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-I DNA in a bacterial artificial chromosome. Mol Ther 3: 591-601. (Pubitemid 32509854)
95. Sanders DA (2004). Ebola virus glycoproteins: guidance devices for targeting gene therapy vectors. Expert Opin Biol Ther 4: 329-336.
96. Sandrin V, Boson B, Salmon P, Gay W, Negre D, Le Grand R et al. (2002). Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates. Blood 100: 823-832. (Pubitemid 34832607)
97. Sandrin V, Muriaux D, Darlix JL, Cosset FL (2004). Intracellular trafficking of Gag and Env proteins and their interactions modulate pseudotyping of retroviruses. J Virol 78: 7153-7164. (Pubitemid 38781554)
98. Sandrin V, Russell SJ, Cosset FL (2003). Targeting retroviral and lentiviral vectors. Curr Top Microbiol Immunol 281: 137-178.
99. Saukkonen K, Hemminki A (2004). Tissue-specific promoters for cancer gene therapy. Expert Opin Biol Ther 4: 683-696. (Pubitemid 38667814)
100. Schambach A, Galla M, Maetzig T, Loew R, Baum C (2007). Improving transcriptional termination of self-inactivating gamma-retroviral and lentiviral vectors. Mol Ther 15: 1167-1173. (Pubitemid 46813620)
101. Schauber-Plewa C, Simmons A, Tuerk MJ, Pacheco CD, Veres G (2005). Complement regulatory proteins are incorporated into lentiviral vectors and protect particles against complement inactivation. Gene Ther 12: 238-245. (Pubitemid 40220625)
102. Sclimenti CR, Thyagarajan B, Calos MP (2001). Directed evolution of a recombinase for improved genomic integration at a native human sequence. Nucleic Acids Res 29: 5044-5051. (Pubitemid 34065420)
103. Sharkey CM, North CL, Kuhn RJ, Sanders DA (2001). Ross River virus glycoprotein-pseudotyped retroviruses and stable cell lines for their production. J. Virol 75: 2653-2659.
104. Shayakhmetov DM, Papayannopoulou T, Stamatoyannopoulos G, Lieber A (2000). Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector. J. Virol 74: 2567-2583. (Pubitemid 30117566)
105. Shimotohno K, Temin HM (1981). Formation of infectious progeny virus after insertion of herpes simplex thymidine kinase gene into DNA of an avian retrovirus. Cell 26: 67-77. (Pubitemid 12229365)
106. Sinn PL, Hickey MA, Staber PD, Dylla DE, Jeffers SA, Davidson BL et al. (2003). Lentivirus vectors pseudotyped with filoviral envelope glycoproteins transduce airway epithelia from the apical surface independently of folate receptor alpha. J. Virol 77: 5902-5910.
107. Spiegel M, Bitzer M, Schenk A, Rossmann H, Neubert WJ, Seidler U et al. (1998). Pseudotype formation of moloney murine leukemia virus with sendai virus glycoprotein F. J. Virol 72: 5269-5302. (Pubitemid 28215718)
108. Sung VM, Lai MM (2002). Murine retroviral pseudotype virus containing hepatitis B virus large and small surface antigens confers specific tropism for primary human hepatocytes: a potential liver-specific targeting system. J. Virol 76: 912-917.
109. Suomalainen M, Garoff H (1994). Incorporation of homologous and heterologous proteins into the envelope of Moloney murine leukemia virus. J. Virol 68: 4879-4889. (Pubitemid 24226553)
110. Sutherland S (2003). Ebola glycoprotein: the key to successful gene therapy? Drug Discov Today 8: 609-610. (Pubitemid 36809250)
111. Szecsi J, Drury R, Josserand V, Grange MP, Boson B, Hartl I et al. (2006). Targeted retroviral vectors displaying a cleavage siteengineered hemagglutinin (HA) through HA-protease interactions. Mol Ther 14:735-744. (Pubitemid 44480752)
112. Tabin CJ, Hoffmann JW, Goff SP, Weinberg RA (1982). Adaptation of a retrovirus as a eucaryotic vector transmitting the herpes simplex virus thymidine kinase gene. Mol Cell Biol 2: 426-436.
113. Takeuchi Y, Cosset FL, Lachmann PJ, Okada H, Weiss RA, Collins MKL (1994). Type C retrovirus inactivation by human complement is determined by both the viral genome and producer cell. J. Virol 68: 8001-8007. (Pubitemid 24362688)
114. Tan W, Dong Z, Wilkinson TA, Barbas III CF, Chow SA (2006). Human immunodeficiency virus type 1 incorporated with fusion proteins consisting of integrase and the designed polydactyl zinc finger protein E2C can bias integration of viral DNA into a predetermined chromosomal region in human cells. J. Virol 80: 1939-1948. (Pubitemid 43228733)
115. Thornhill SI, Schambach A, Howe SJ, Ulaganathan M, Grassman E, Williams D et al. (2008). Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency. Mol Ther 16: 590-598. (Pubitemid 351315000)
116. Thrasher AJ, Gaspar HB (2007). Severe Adverse Event in Clinical Trial of Gene Therapy for X-SCID, http://www.esgct.org/upload/XSCID-statement-AT.pdf.
117. Thrasher AJ, Gaspar HB, Baum C, Modlich U, Schambach A, Candotti F et al. (2006). Gene therapy: X-SCID transgene leukaemogenicity. Nature 443: E5-E6; discussion E6-E7. (Pubitemid 44435140)
118. Uchiyama T, Kumaki S, Ishikawa Y, Onodera M, Sato M, Du W et al. (2006). Application of HSVtk suicide gene to X-SCID gene therapy: ganciclovir treatment offsets gene corrected X-SCID B cells. Biochem Biophys Res Commun 341: 391-398. (Pubitemid 43152119)
119. Vasileva A, Jessberger R (2005). Precise hit: adeno-associated virus in gene targeting. Nat Rev Microbiol 3: 837-847. (Pubitemid 41693179)
120. Verhoeyen E, Cosset FL (2004). Surface-engineering of lentiviral vectors. J Gene Med 6 (Suppl 1): S83-S94.
121. Verhoeyen E, Dardalhon V, Ducrey-Rundquist O, Trono D, Taylor N, Cosset F-L (2003). IL-7 surface-engineered lentiviral vectors promote survival and efficient gene transfer in resting primary T-lymphocytes. Blood 101: 2167-2174. (Pubitemid 36302054)
122. Verhoeyen E, Wiznerowicz M, Olivier D, Izac B, Trono D, DubartKupperschmitt A et al. (2005). Novel lentiviral vectors displaying 'early-acting cytokines' selectively promote survival and transduction of NOD/SCID repopulating human hematopoietic stem cells. Blood 106: 3386-3395.
123. Wade-Martins R, Saeki Y, Chiocca EA (2003). Infectious delivery of a 135-kb LDLR genomic locus leads to regulated complementation of low-density lipoprotein receptor deficiency in human cells. Mol Ther 7: 604-612. (Pubitemid 36626240)
124. Waehler R, Russell SJ, Curiel DT (2007). Engineering targeted viral vectors for gene therapy. Nat Rev Genet 8: 573-587. (Pubitemid 47077278)
125. Wei CM, Gibson M, Spear PG, Scolnick EM (1981). Construction and isolation of a transmissible retrovirus containing the src gene of Harvey murine sarcoma virus and the thymidine kinase gene of herpes simplex virus type 1. J. Virol 39: 935-944. (Pubitemid 11059892)
126. Weidhaas JB, Angelichlo EL, Fenner S, Coffin JM (2000). Relationship between retroviral DNA integration and gene expression. J. Virol 74: 8382-8389. (Pubitemid 30666689)
127. Wool-Lewis RJ, Bates P (1998). Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines. J. Virol 72: 3155-3160.
128. Wu Z, Asokan A, Grieger JC, Govindasamy L, Agbandje-McKenna M, Samulski RJ (2006a). Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adenoassociated virus serotypes. J. Virol 80: 11393-11397. (Pubitemid 44706580)
129. Wu Z, Asokan A, Samulski RJ (2006b). Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther 14: 316-327. (Pubitemid 44184972)
130. Yu JH, Schaffer DV (2005). Advanced targeting strategies for murine retroviral and adeno-associated viral vectors. Adv Biochem Eng Biotechnol 99: 147-167.
131. Yu SF, von Ruden T, Kantoff PW, Garber C, Seiberg M, Rüther U et al. (1986). Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc Natl Acad Sci USA 83: 3194-3198.
132. Zaiss AK, Muruve DA (2008). Immunity to adeno-associated virus vectors in animals and humans: a continued challenge. Gene Ther 15: 808-816.
133. Zaupa C, Revol-Guyot V, Epstein AL (2003). Improved packaging system for generation of high-level noncytotoxic HSV-1 amplicon vectors using Cre-loxP site-specific recombination to delete the packaging signals of defective helper genomes. Hum Gene Ther 14: 1049-1063. (Pubitemid 36851397)